Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Roche holding ag - Caught on Camera

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Therefore, it could be wise to keep an eye on top pharma stocks, Roche Holding (RHHBY), Novartis (NVS) and AbbVie (ABBV). Continue reading.

StockNews.com · Dec 20, 2023

3 Booming Pharma Stocks Making Waves in the Industry

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Given this backdrop, it could be wise to buy Roche Holding (RHHBY), AstraZeneca (AZN) and Bristol-Myers Squibb (BMY), which look poised for steady returns. Keep reading.

StockNews.com · Nov 13, 2023

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

Tribune News Service · Nov 6, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Bargain-Hunting: 3 Mega-Cap Pharmaceutical Stocks to Buy and Hold

Although the heightened market volatility has caused several pharma stocks to slump in price, the sector’s long-term prospects look bright. This sector has been attracting massive investments and could remain in the limelight in the near term. So, we think it should be wise to buy and hold mega-cap pharmaceutical…

StockNews.com · Jun 16, 2022

2 Mega-Cap Stocks to Buy on the Dip

Mega-cap stocks Walmart (WMT) and Roche Holding (RHHBY) are both down more than 15% in the past month but could be solid buy the dip candidates.

StockNews.com · May 17, 2022

Roche Releases More Evrysdi Data For Very Young Infants With SMA

Roche Holding AG's (OTC:RHHBY) Genentech has released new long-term data on its oral drug for spinal muscular atrophy (SMA). After three years of treatment, 91% of children who began taking the drug at ages 1-7 months were alive (n=58). In addition, of 48 children evaluated, 32 maintained, and four gained the ability to…

Benzinga · Apr 29, 2022

SoftBank Loses Vision Fund Leader; Continues To Liquidate Portfolio

Ron Fisher looked to depart as the head of SoftBank Group Corp's (OTC:SFTBY) (OTC:SFTBF) Vision Fund and Chair and director of SoftBank Investment Advisors U.S. on April 15, Bloomberg reports. Fisher would remain a senior advisor to SoftBank's founder and CEO, Masayoshi Son. Fisher left SoftBank's board in 2021. Fisher began working with…

Benzinga · Apr 4, 2022

Read news from The Economist, FT, and more,
with one subscription

Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial

Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)

Benzinga · Mar 30, 2022

US FDA Advisers Say More Data Needed for Cancer Drug Tested in China

A panel of outside advisers to the US Food and Drug Administration on Thursday voted to recommend that Innovent Biologics Inc and Eli Lilly and Co be required to conduct a trial of their lung cancer drug that is applicable to the US population. Data submitted to the FDA for…

Asharq Al-Awsat · Feb 11, 2022

Coverage From

People

Masayoshi Son

140 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

BristolMyers Squibb Company

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.